Why did my GGT move after four weeks on retatrutide?

Setup, so nobody has to ask: GGT · four weeks · retatrutide.

I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact.

I want to know whether this is recoverable or whether the honest answer is to write it off.

Should I be treating this as a failure or as noise?

4 weeks is 28 days, and the first question about any marker is whether 28 days is long enough for it to have finished moving. GGT turns over slowly, over two to three weeks, and responds to hepatic fat and to alcohol with roughly equal enthusiasm. Against 28 days the marker is at or near the edge of its own settling time, so part of what you are reading is the transition rather than the destination. The second question is the denominator. Weight loss moves plasma volume, muscle mass and intake at once, and several of the markers on a routine panel are ratios with one of those three underneath them. Repeat before interpreting. A single value 28 days in, with no baseline drawn under the same conditions, is a number rather than a change — and nothing here is medical advice.

Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Keep the full report, not the number. You will need the units and the interval later.

edited 1 May 2026 by Dr_Rosalind_Achebe — added the method parameters

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Decide the action for each result before you order the test.

Specifically, this is answerable, and the answer is mostly about which tests rather than how many.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.